Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP9 | Q86TI2 | 11/20 | 0.58 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.58 |
| ▸ | DPP4 | P27487 | 8/20 | 0.58 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.58 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.51 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.51 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.50 |
| ▸ | FAP | Q12884 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30261110 | 0.86 | ALDH1A1 (0.51) | DPP9DPP8DPP4DPP7 | |
| SCHEMBL13892124 | 0.86 | ALDH1A1 (0.51) | DPP9DPP8DPP4DPP7 | |
| SCHEMBL30142417 | 0.83 | DPP9 (0.63) | DPP9DPP8DPP4DPP7HSP90B1 | |
| SCHEMBL19926225 | 0.79 | MEN1 (0.37) | DPP9DPP8DPP4DPP7HSP90B1 | |
| SCHEMBL24814735 | 0.79 | DPP9 (0.55) | DPP9DPP8DPP4DPP7HSP90B1 | |
| SCHEMBL30684946 | 0.79 | DPP9 (0.55) | DPP9DPP8DPP4DPP7HSP90B1 | |
| SCHEMBL29986254 | 0.79 | DPP9 (0.55) | DPP9DPP8DPP4DPP7HSP90B1 | |
| SCHEMBL29824272 | 0.79 | DPP9 (0.56) | DPP9DPP8DPP4DPP7TAS1R3 | |
| SCHEMBL8401777 | 0.79 | DPP9 (0.62) | DPP9DPP8DPP4DPP7HSP90B1 | |
| SCHEMBL3773132 | 0.78 | ABHD6 (0.54) | HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | MEBIAS DISCOVERY, INC. | 2020-10-01 | — | — | US | claimed |
| EP-3506983-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | Mebias Discovery LLC (US) | 2019-07-10 | — | — | EP | claimed |
| US-20190194178-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC | 2019-06-27 | — | — | US | claimed |
| WO-2018045229-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC (US) | 2018-03-08 | — | — | WO | claimed |
| US-9233111-B2 | Pyrrolo pyrimidine derivatives | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | claimed |
| EP-2729466-B1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-08-19 | — | — | EP | claimed |
| US-20140243306-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | claimed |
| EP-2729466-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2014-05-14 | — | — | EP | claimed |
| WO-2013008095-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | claimed |
| US-11198685-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | MEBIAS DISCOVERY, INC. | 2020-10-01 | — | — | US | disclosed |
| US-10683283-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| EP-3506983-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | Mebias Discovery LLC (US) | 2019-07-10 | — | — | EP | disclosed |
| US-20190194178-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC | 2019-06-27 | — | — | US | disclosed |
| EP-2729466-B1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-20140243306-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| EP-2729466-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013008095-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| EP-2205564-A1 | NOVEL KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009053269-A1 | NOVEL KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683283-B2 | Substituted ureas and methods of making and using same | UMPS, METTL3, UTS2R | DPP9 3471/4885DPP8 2925/4885DPP4 2874/4885 |
| US-20190194178-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | UMPS, METTL3, UTS2R | DPP9 3471/4885DPP8 2925/4885DPP4 2874/4885 |
| US-11198685-B2 | Substituted ureas and methods of making and using same | UMPS, METTL3, UTS2R | DPP9 3471/4885DPP8 2925/4885DPP4 2874/4885 |
| US-20140243306-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | BTK, LCK, ZAP70 | DPP9 2372/4885DPP8 3390/4885DPP4 2678/4885 |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | UMPS, METTL3, UTS2R | DPP9 3471/4885DPP8 2925/4885DPP4 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.